论文部分内容阅读
目的分析替普瑞酮对慢性萎缩性胃炎转归的作用。方法 96例慢性萎缩性胃炎患者,随机分成对照组与观察组,各48例。对照组给予常规治疗,观察组在常规治疗基础上应用替普瑞酮治疗。比较两组的症状评分情况和临床治疗效果。结果治疗前两组患者的症状评分比较差异无统计学意义(P>0.05),治疗后观察组的症状评分(0.24±0.07)分,优于对照组的(1.21±0.12)分,差异有统计学意义(t=46.838,P<0.05)。观察组治疗总有效率为93.8%,明显高于对照组的66.7%,差异有统计学意义(P<0.05)。治疗后对两组幽门螺杆菌分别进行了检查,观察组与对照组的幽门螺杆菌转阴率分别为83.3%(40例)与79.2%(38例),两组比较差异无统计学意义(P>0.05)。结论替普瑞酮对慢性萎缩性胃炎转归的作用显著,可有效的改善患者的临床症状,抑制幽门螺杆菌,具有显著的治疗作用,值得在临床中广泛的应用。
Objective To analyze the effect of teprenone on the outcome of chronic atrophic gastritis. Methods 96 patients with chronic atrophic gastritis were randomly divided into control group and observation group, 48 cases each. The control group was given routine treatment. The observation group was treated with teprenone on the basis of routine treatment. Symptom scores and clinical outcomes were compared between the two groups. Results There was no significant difference in symptom scores between the two groups before treatment (P> 0.05). After treatment, the symptom scores of the observation group (0.24 ± 0.07) were better than those of the control group (1.21 ± 0.12) Significance (t = 46.838, P <0.05). The total effective rate of observation group was 93.8%, significantly higher than 66.7% of the control group, the difference was statistically significant (P <0.05). Helicobacter pylori in both groups were examined after treatment. The negative conversion rates of Helicobacter pylori in observation group and control group were 83.3% (40 cases) and 79.2% (38 cases), respectively. There was no significant difference between the two groups P> 0.05). Conclusion The effect of teprenone on the prognosis of chronic atrophic gastritis is significant, which can effectively improve the clinical symptoms and inhibit the helicobacter pylori infection. It has a significant therapeutic effect and deserves to be widely used clinically.